- Category: HBV Treatment
- Published on Thursday, 13 April 2017 00:00
- Written by Liz Highleyman
The European Association for the Study of the Liver (EASL) International Liver Congress (ILC 2016) will take place April 19-23 at the RAI Centre in Amsterdam. The congress is one of the major annual scientific meetings covering hepatitis B and C and its complications, as well as other liver diseases. HIVandHepatitis.com and our partners at aidsmap.com will be providing on-site coverage of meeting highlights.
Now that interferon-free direct-acting antiviral regimens can cure most people with chronic hepatitis C in 8 to 12 weeks, researchers have turned their attention to treating the remaining most challenging patients and the prospect of eliminating HCV as a public health threat. Many sessions will focus on broadening access to therapy, as well as ongoing screening and management of liver disease -- especially hepatocellular carcinoma -- in people who have been cured of hepatitis C.
Several presentations will look at novel therapies for hepatitis B. Current antiviral agents can suppress HBV viral load, but seldom lead to a cure. In addition, the hepatology field is devoting more attention to fatty liver disease as a growing cause of cirrhosis and liver cancer.
Follow @HIVandHepatitis on Twitter for breaking news coverage and visit www.HIVandHepatitis.comand aidsmap.com for the latest news reports. Abstracts, webcasts, and other conference material will be available on the International Liver Congress websiteas it is released from embargo.
EASL. International Liver Congress. http://ilc-congress.eu.